Experts Highlight ASH 2025 Data Transforming Treatment for Hematologic Cancers

The recent presentations at the 2025 ASH Annual Meeting and Exposition have revealed groundbreaking data that could significantly alter treatment approaches for several hematologic malignancies. Experts highlighted key studies that indicate a shift in management strategies for acute myeloid leukemia (AML), marginal zone lymphoma (MZL), and multiple myeloma, emphasizing the potential of low-intensity regimens and novel therapies.

During the event, the PARADIGM study drew considerable attention for its comparison of venetoclax and azacitidine against traditional intensive chemotherapy. Research findings presented at the meeting suggested that the combination therapy is not only better tolerated but may also offer superior benefits for many patients. Dr. Andorsky noted, “Having randomized data demonstrating both those findings is really exciting and is probably going to change practice going forward.”

Dr. Jen added that the results indicate a potential expansion of azacitidine and venetoclax use beyond the current indication for patients over 75 years old, as the median age of participants in the study was somewhat older. This suggests a promising avenue for treatment in younger patients as well.

The implications of the PARADIGM trial are profound. Dr. Arora emphasized that the study challenges long-standing views, stating, “Historically, we’ve always said that fit patients get 7+3 chemotherapy, while older, unfit patients get hypomethylating agents and venetoclax.” He noted that the trial demonstrated that for certain subtypes of AML, the HMAs combined with venetoclax could lead to better outcomes even in fit, newly diagnosed patients. However, he cautioned about the trial’s exclusion criteria, which included patients with TP53 mutations and NPM1 mutations, indicating that further clarity is needed in how these findings are communicated to the broader medical community.

The potential shift towards lower-intensity regimens is significant. Dr. Goulart remarked that there might be a transition away from more intensive chemotherapy towards HMA-based regimens for patients traditionally receiving more aggressive treatments, especially if safe transplant options are available.

Turning to MZL, Dr. Kamdar highlighted the promising long-term data from the TRANSCEND FL trial involving liso-cel. Following three years of follow-up, the therapy demonstrated impressive benefits for patients with high tumor burden and early progressing disease. This culminated in a pivotal moment on December 4, 2025, when the FDA approved liso-cel for relapsed/refractory MZL in the third-line setting, offering hope for patients facing this challenging condition.

In the realm of multiple myeloma, the phase 3 MajesTEC-3 trial presented compelling data on teclistamab, a bispecific antibody targeting BCMA and CD3. Dr. Cerchione stated that the combination of teclistamab with daratumumab showed remarkable depth of response and progression-free survival, while also reducing the need for dexamethasone. This adjustment correlates with improved quality of life for patients, though he noted the study began in 2021 before current toxicity management strategies were established.

Dr. Cerchione also discussed the promising developments in frontline therapies, such as linvoseltamab, which is under evaluation in the phase 1/2 LINKER-MM4 trial. The initial results indicate high response rates among both transplant-eligible and ineligible patients with newly diagnosed multiple myeloma.

Dr. Biran emphasized the importance of research in the post-transplant setting, noting that linvoseltamab’s results in a phase 1b trial showed nearly a 100% minimal residual disease negativity rate after six months of therapy. This finding is poised to drive further studies investigating T-cell engagers and other innovative therapies in this context.

The insights from the 2025 ASH Annual Meeting underscore a pivotal moment in the treatment landscape for hematologic malignancies. With a clear trend towards low-intensity therapies and novel agents, patients may soon benefit from more effective and tolerable treatment options. The discussions and findings presented at the conference are likely to influence practice and improve outcomes in these challenging conditions for years to come.